fbpx

Conventional Multidisciplinary Treatments for Mesothelioma.

Share Button

“Individualization of care for each mesothelioma patient is fundamental in choosing the most appropriate treatment. The growing complexity of treatment protocols mandates that MPM patients be referred to specialized Centers..”

Image result for image of hyperthermia for lung cancer

The bottom line is that mesothelioma is an aggressive, complicated cancer. As the first study linked and excerpted below explains each patient must be treated differently. In previous mesothelioma blog posts I have advocated that meso patients see oncologists who specialize in treating mesothelioma.

Having said the above I am quick to add the importance of learning about and adding both integrative and complimentary therapies to your meso treatment.

I am a long-term survivor of a completely different but equally incurable cancer called multiple myeloma. I achieved complete remission (in 1999) from my cancer by searching out evidence-based, non-conventional therapies and I encourage mesothelioma patients to do the same.

If you would like to ask a question or make a comment please scroll down the page, write a post and I will rely to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.

Malignant pleural mesothelioma (MPM) is an aggressive neoplasia. Multidisciplinary treatments, including the association of induction and/or adjuvant therapeutic regimens with surgery, have been reported to give encouraging results. Current therapeutic options are not well standardized yet, especially regarding the best association between surgery and medical treatments

Individualization of care for each patient is fundamental in choosing the most appropriate treatment. The growing complexity of treatment protocols mandates that MPM patients be referred to specialized Centers, in which every component of the interdisciplinary team can provide the necessary expertise and quality of care…”

Malignant peritoneal mesothelioma.

“This paper summarizes the author’s thoughts about the use of cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy (CS-IPHC) for treatment of peritoneal malignant mesothelioma

It is well known that chemotherapy for mesothelioma is largely unsatisfactory, and measurement of treatment responses can be difficult. Single agent responses are all less than 20% with currently available agents for systemically administered drugs. Multiple drug combinations are typically more toxic, and have yielded little consistent demonstrable benefit with major studies reporting median survivals consistently under a year…

The author’s approach relies on surgery to achieve the following: 1) accurate staging; 2) tumor debulking, as possible, and treatment of mechanical obstruction as well as prevention of impending obstruction by resection or bypass; and 3) preparation for the use of intra-operative hyperthermic chemotherapy perfusion. This approach has been associated with rapid clinical symptom improvement, as well as a reliable and durable resolution of ascites with a single therapy. Morbidity and mortality have been acceptable with about 27-month median survival…”

First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.

“Results-¬†Two complete responses and 9 partial responses were achieved. Overall response rate and disease control rate were 45.8% and 91.7%, respectively. Median progression-free survival and median overall survival were 11.0 months and 15.8 months, respectively…

Conclusions-¬†Systemic pemetrexed plus cisplatin is active for MPeM. Disparity with the outcome of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) needs to receive more emphasis, since peritoneal mesothelioma has a 5-year survival rate of 50%…”

 

Leave a Comment: